[Opioid crisis in the USA: what are implications for Switzerland?]

Autor:	Bertholet N; Service de médecine des addictions, Département de psychiatrie, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne., Araiedh J; Service de médecine des addictions, Département de psychiatrie, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne., Englander H; Section of addiction medicine in general internal medicine, Department of medicine, Oregon Health & Science University, 3266 SW Research Dr, Portland, Orégon 97239, États-Unis.; Service universitaire d'addictologie de Lyon, Centre hospitalier Le Vinatier, 69678 Bron, France.
Jazyk:	francouzština
Zdroj:	Revue medicale suisse [Rev Med Suisse] 2024 Sep 18; Vol. 20 (887), pp. 1660-1663.
DOI:	10.53738/REVMED.2024.20.887.1660
Abstrakt:	Warnings in Europe signal a rise in illicitly-manufactured fentanyl and other high potency synthetic opioids which could destabilize drug markets, strain health systems, and escalate harms of substance use and death. Here, we provide an overview of fentanyl in North America, drawing implications for Switzerland. Fentanyl withdrawal starts sooner, is more severe, and has worse anxiety and pain. Clinical care includes aggressive use of full agonist opioids, opioid agonist therapies (OAT) and adjunctive medications for acute withdrawal, and a need for low-threshold, readily accessible OAT to engage patients and mitigate harms. The US experience suggests the importance of widespread naloxone distribution, peer-based initiatives, early warning systems, and partnerships across patient-groups, healthcare systems, and public health. Competing Interests: Les auteur-es n’ont déclaré aucun conflit d’intérêts en relation avec cet article
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu